Overview

Subantimicrobial Doxycycline in Acne

Status:
Completed
Trial end date:
2021-11-08
Target enrollment:
Participant gender:
Summary
Antibiotic resistance is a public health problem that worsens the more we prescribe standard dose antibiotics for acne. Regardless of race, acne vulgaris is one of the most common dermatologic conditions among pediatric populations. As such, we can make a large impact by practicing good antibiotic stewardship while still addressing the impact of acne on adolescents' self-esteem. Subantimicrobial doxycycline maintains its anti-inflammatory effects while eliminating antimicrobial properties and associated risks of drug resistance. Few studies, focused primarily on adults, have shown that subantimicrobial doxycycline is efficacious in treating acne from a physician standpoint. We aim to investigate the patient experience of acne treatment with subantimicrobial dose doxycycline in the pediatric population.
Phase:
Phase 4
Details
Lead Sponsor:
Michigan State University
Treatments:
Doxycycline